Long-term use of adalimumab in the treatment of rheumatic diseases

Charalampos Papagoras, Paraskevi&nbsp;V Voulgari, Alexandros A DrososRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, GreeceAbstract: Adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor-alpha (TNF&alph...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Charalampos Papagoras, Paraskevi&nbsp;V Voulgari, Alexandros A Drosos
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/43f28b6a51da4deab3b66a59004132da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43f28b6a51da4deab3b66a59004132da
record_format	dspace
spelling	oai:doaj.org-article:43f28b6a51da4deab3b66a59004132da2021-12-02T01:32:31ZLong-term use of adalimumab in the treatment of rheumatic diseases1179-156Xhttps://doaj.org/article/43f28b6a51da4deab3b66a59004132da2009-05-01T00:00:00Zhttp://www.dovepress.com/long-term-use-of-adalimumab-in-the-treatment-of-rheumatic-diseases-a3155https://doaj.org/toc/1179-156XCharalampos Papagoras, Paraskevi&nbsp;V Voulgari, Alexandros A DrososRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, GreeceAbstract: Adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor-alpha (TNF&alpha;), has been evaluated in various randomized placebo-controlled trials in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In the short time frame of these trials adalimumab has been shown to be effective in reducing disease activity, slowing radiographic disease progression and improving patients&rsquo; quality of life, while at the same time demonstrating an acceptable safety profile. Furthermore, release of adalimumab on the market, prospective observational studies, as well as open-label extensions of the original double-blind trials have provided experience and data about the long-term efficacy and safety of the drug. Initial effectiveness, in terms of reducing disease activity, is sustained, while in most cases patients treated with adalimumab experienced a slower radiographic progression and consequently less disability and improved health-related quality-of-life outcomes. Moreover, long-standing treatment of thousands of patients with adalimumab outside the controlled context of clinical trials was not related to new safety signals, with the most common adverse events being respiratory infections. The most common serious adverse events seem to be tuberculosis reactivation, while a putative association with malignant lymphoma development is not yet proven. Besides, both of these adverse reactions pertain to the whole TNF&alpha; blocker group. In conclusion, adalimumab is a safe and effective option for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. Keywords: adalimumab, tumor necrosis factor-alpha, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis Charalampos PapagorasParaskevi&nbsp;V VoulgariAlexandros A DrososDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2009, Iss default, Pp 51-68 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Charalampos Papagoras Paraskevi&nbsp;V Voulgari Alexandros A Drosos Long-term use of adalimumab in the treatment of rheumatic diseases
description	Charalampos Papagoras, Paraskevi&nbsp;V Voulgari, Alexandros A DrososRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, GreeceAbstract: Adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor-alpha (TNF&alpha;), has been evaluated in various randomized placebo-controlled trials in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In the short time frame of these trials adalimumab has been shown to be effective in reducing disease activity, slowing radiographic disease progression and improving patients&rsquo; quality of life, while at the same time demonstrating an acceptable safety profile. Furthermore, release of adalimumab on the market, prospective observational studies, as well as open-label extensions of the original double-blind trials have provided experience and data about the long-term efficacy and safety of the drug. Initial effectiveness, in terms of reducing disease activity, is sustained, while in most cases patients treated with adalimumab experienced a slower radiographic progression and consequently less disability and improved health-related quality-of-life outcomes. Moreover, long-standing treatment of thousands of patients with adalimumab outside the controlled context of clinical trials was not related to new safety signals, with the most common adverse events being respiratory infections. The most common serious adverse events seem to be tuberculosis reactivation, while a putative association with malignant lymphoma development is not yet proven. Besides, both of these adverse reactions pertain to the whole TNF&alpha; blocker group. In conclusion, adalimumab is a safe and effective option for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. Keywords: adalimumab, tumor necrosis factor-alpha, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis
format	article
author	Charalampos Papagoras Paraskevi&nbsp;V Voulgari Alexandros A Drosos
author_facet	Charalampos Papagoras Paraskevi&nbsp;V Voulgari Alexandros A Drosos
author_sort	Charalampos Papagoras
title	Long-term use of adalimumab in the treatment of rheumatic diseases
title_short	Long-term use of adalimumab in the treatment of rheumatic diseases
title_full	Long-term use of adalimumab in the treatment of rheumatic diseases
title_fullStr	Long-term use of adalimumab in the treatment of rheumatic diseases
title_full_unstemmed	Long-term use of adalimumab in the treatment of rheumatic diseases
title_sort	long-term use of adalimumab in the treatment of rheumatic diseases
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/43f28b6a51da4deab3b66a59004132da
work_keys_str_mv	AT charalampospapagoras longtermuseofadalimumabinthetreatmentofrheumaticdiseases AT paraskeviampnbspvvoulgari longtermuseofadalimumabinthetreatmentofrheumaticdiseases AT alexandrosadrosos longtermuseofadalimumabinthetreatmentofrheumaticdiseases
_version_	1718403009446150144

Long-term use of adalimumab in the treatment of rheumatic diseases

Ejemplares similares